D2 dopamine receptor gene polymorphism: paroxetine and social functioning in posttraumatic stress disorder
Autor: | Bruce R. Lawford, Terry Ritchie, Ross McD. Young, Leanne Arnold, Burnett Kann, Ernest P. Noble, J. Rowell |
---|---|
Rok vydání: | 2003 |
Předmět: |
Male
Oncology medicine.medical_specialty TaqI Serotonin reuptake inhibitor chemistry.chemical_compound Internal medicine medicine Humans Pharmacology (medical) Social Behavior Alleles Biological Psychiatry Depression (differential diagnoses) Pharmacology Analysis of Variance Chi-Square Distribution Polymorphism Genetic Receptors Dopamine D2 Middle Aged Epilepsy Post-Traumatic Paroxetine Psychiatry and Mental health Neurology chemistry Dopamine receptor Anxiety Neurology (clinical) Gene polymorphism medicine.symptom Psychology medicine.drug Clinical psychology Psychopathology |
Zdroj: | European Neuropsychopharmacology. 13:313-320 |
ISSN: | 0924-977X |
DOI: | 10.1016/s0924-977x(02)00152-9 |
Popis: | This study examined whether allelic status of the D2 dopamine receptor (DRD2) gene was associated with response to a selective serotonin reuptake inhibitor, paroxetine, in the treatment of posttraumatic stress disorder (PTSD). Sixty-three Caucasian war veterans with combat-related PTSD were treated with paroxetine for 8 weeks. Patients were assessed at baseline and at follow-up using the General Health Questionnaire-28 (GHQ). TaqI A DRD2 alleles were determined by PCR. Before paroxetine treatment, patients with the DRD2 A1+ allele (A1A2 genotype) compared to those with the A1- allele (A2A2 genotype) had higher total GHQ psychopathological scores (P=0.040) and higher GHQ subscale scores for anxiety/insomnia (0.046), social dysfunction (P=0.033) and depression (P=0.011). In an intention-to-treat analysis, paroxetine was associated with significant improvement in total GHQ scores (P=0.014) and in the factor scores of social dysfunction (P=0.033), anxiety (P=0.009) and depression (P=0.026). Furthermore, there was a significant allele by time interaction on the social dysfunction scale, with A1+ allelic patients showing significant improvement in social functioning compared to A1- allelic patients (P=0.031), an effect independent of changes in depression or anxiety. This suggests changes in social functioning induced by paroxetine may be, in part, mediated via D2 dopamine receptors. The DRD2 A1 allele may prove to be a useful marker to assist clinicians in predicting which patients with PTSD are likely to obtain improvements in social functioning with paroxetine treatment. |
Databáze: | OpenAIRE |
Externí odkaz: |